



## Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

May 28, 2024

CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies Global Healthcare Conference and the Goldman Sachs 45<sup>th</sup> Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

### Jefferies Global Healthcare Conference

- Presentation: Wednesday, June 5, 2024, at 3:30 p.m. ET at the Marriott Marquis New York, New York
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast [here](#)
- Management will also participate in one-on-one meetings on Wednesday, June 5

### Goldman Sachs 45<sup>th</sup> Annual Global Healthcare Conference

- Presentation: Monday, June 10, 2024, at 3:20 p.m. ET at the Loews Miami Beach Hotel, Miami Beach, Florida
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast [here](#)
- Management will also participate in one-on-one meetings during the conference

A webcast of both presentations can be accessed under "[Events & Presentations](#)" in the Investors section of the Company's website, [www.foghornrx.com](http://www.foghornrx.com), and will be available for 30 days.

### About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at [www.foghornrx.com](http://www.foghornrx.com) for more information about the Company, and follow us on [X](#) (formerly Twitter) and [LinkedIn](#).

### Contacts:

Greg Dearborn, Foghorn Therapeutics Inc. (Investors)  
[gdearborn@foghornrx.com](mailto:gdearborn@foghornrx.com)

Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)  
[khellsvik@foghornrx.com](mailto:khellsvik@foghornrx.com)

Adam Silverstein, ScientPR (Media)  
[adam@scientpr.com](mailto:adam@scientpr.com)